Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (174)

« Back to Publications

Pooled analysis of PCV13 efficacy from controlled human infection trials in Malawi and the UK.

Kudowa E. et al, (2026), NPJ Vaccines

Controlled human pneumococcal infection in the Netherlands: Colonisation, antibody responses and the impact of viral co-infection.

van Beek LF. et al, (2026), J Infect, 92

The effect of pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine on nasopharyngeal colonisation following human infection challenge with serotype 3 and serotype 6B (PREVENTING PNEUMO 2): a double-masked, randomised, controlled, phase 4 trial.

Liatsikos K. et al, (2026), Lancet Microbe

13-valent pneumococcal conjugate vaccine-induced B cells produce serotype 6B but not serotype 3 capsule-specific IgG antibodies in young Malawian adults.

Tembo G. et al, (2026), Vaccine, 75

Persistent pneumococcal colonisation in antiretroviral-treated HIV infection is associated with nasal inflammation.

Phiri JA. et al, (2025), Nat Commun, 17

Controlled human infection model (CHIM) inoculum production in Malawi using principles of good manufacturing practice

Chikaonda T. et al, (2025), Vaccine X, 27

Protocol for a phase IV, Experimental Human Pneumococcal Challenge (EHPC) model to investigate Streptococcus pneumoniae serotype 3 (SPN3) colonisation following PCV15, a double-blind randomised controlled trial in healthy participants aged 18-50 years in the UK (RATIONALE-15).

Macedo BRD. et al, (2025), BMJ Open, 15

Machine learning-driven identification of serotype-independent pneumococcal vaccine candidates using samples from human infection challenge studies

Cheliotis KS. et al, (2025)

Machine Learning-Driven Identification of Serotype-Independent Pneumococcal Vaccine Candidates using samples from Human Infection Challenge Studies

Cheliotis KS. et al, (2025)

High Propensity for Multidrug-Resistant Pneumococcal Shedding Among Adults Living With HIV on Stable Antiretroviral Therapy in Malawi.

Sibale LL. et al, (2025), Open Forum Infect Dis, 12

Pneumococcal Carriage and Disease in Adults in England, 2011-2019: The Importance of Adults as a Reservoir for Pneumococcus in Communities.

El Safadi D. et al, (2025), J Infect Dis, 231, e17 - e27

Understanding the interaction of upper respiratory tract infection with respiratory syncytial virus and Streptococcus pneumoniae using a human challenge model: a multicenter, randomized controlled study protocol.

Brito-Mutunayagam S. et al, (2025), PLoS One, 20

Essential role of proline synthesis and the one-carbon metabolism pathways for systemic virulence of Streptococcus pneumoniae.

Ramos-Sevillano E. et al, (2024), mBio, 15

Inflammation of the nasal mucosa is associated with susceptibility to experimental pneumococcal challenge in older adults.

Urban BC. et al, (2024), Mucosal Immunol, 17, 973 - 989

Estimating pneumococcal carriage dynamics in adults living with HIV in a mature infant pneumococcal conjugate vaccine programme in Malawi, a modelling study.

Phiri J. et al, (2024), BMC Med, 22

Load More

1
2
3
4
5
6
7
...
»